Previous Article | Next Article ![]()
Molecular and Cellular Biology, July 2005, p. 5712-5724, Vol. 25, No. 13
0270-7306/05/$08.00+0 doi:10.1128/MCB.25.13.5712-5724.2005
Laboratory of Gene Regulation and Development, National Institute of Child Health and Human Development, National Institutes of Health, Bldg. 18T, Rm. 106, Bethesda, Maryland 20892
Received 14 September 2004/ Returned for modification 19 October 2004/ Accepted 25 March 2005
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
In vitro and cell culture studies have led to the isolation and characterization of many TR-interacting cofactor complexes (31, 34, 48, 75, 79). Among them, the best-studied corepressor complexes are those containing the nuclear receptor corepressor N-CoR (27) and the silencing mediator of retinoid and thyroid hormone receptor SMRT (7). Both N-CoR and SMRT exist in multiple histone deacetylase (HDAC)-containing complexes (23, 34, 40, 79). Recent studies suggest that TR most likely utilizes the complexes that contain HDAC3 and TBL1 (for transducin beta-like protein 1) or TBLR1 (for TBL1-related protein) (23, 28, 40, 63, 64, 76, 78).
Among the coactivators that interact with TR directly, the steroid receptor coactivator (SRC) family, which comprises three members (SRC1/NCoA-1, SRC2/TIF2/GRIP1, and SRC3/pCIP/ACTR/AIB-1/RAC-3/TRAM-1) has been the focus of intense studies (6, 26, 39, 45, 61, 68). The SRC proteins bind TR and other nuclear receptors in a ligand-dependent manner through LXXLL (L, leucine; X, any amino acid) motifs, which are indispensable for the interaction (11, 24, 45, 67, 68). The LXXLL motifs form short amphipathic
-helices, with the leucine residues forming a hydrophobic surface on one face of the helix (44, 59, 65). These motifs bind a hydrophobic cleft in the ligand-binding domain of liganded nuclear receptors (13). Three such LXXLL motifs are localized in the central region of these proteins and form the receptor interaction domain (RID). SRC proteins function as bridging factors to recruit chromatin-modifying enzymes, including methylases and histone acetyltransferases.
It remains to be determined how TR utilizes these coactivators in vivo, especially during development when TR regulates different genes in different cell types. This lack of information on the in vivo function of the coactivators in developmental gene regulation by TR is attributed largely to the difficulty in studying TR function in the uterus-enclosed mammalian embryos, despite the fact that T3 deficiency has long been known to cause severe developmental defects, including cretinism (25). The effects of T3 on development take place mainly during perinatal period, when T3 levels in the plasma are high (4, 25, 37).
It is unclear whether and how TR mediates the developmental effects of T3 because of the existence of nongenomic mechanisms through cytosolic T3-binding proteins (10). Studies with TR knockout mice have provided some in vivo evidence to support a critical role of TRs in mediating T3 signal in development. Interestingly, mice lacking TR
or TRß or both have much less severe developmental defects than those lacking T3 (15-17, 20, 22, 70). Furthermore, transgenic mice harboring a dominant negative form of the corepressor N-CoR containing only the receptor-interacting domain in the liver exhibit upregulated T3-inducible genes (14). Finally, many studies with tissue culture cells and frog oocytes show that the bulk of the increases in target gene expression by T3 appears to be due to the release of repression caused by unliganded TR. These studies thus leave unresolved the possibility that corepressor release, not coactivator recruitment, may be the major effect of T3 on gene regulation during development.
Here, we use amphibian metamorphosis as a model to study the role of coactivators in T3 function during development. Amphibian metamorphosis is a T3-dependent process that bears strong similarities to postembryonic development in mammals (56, 62). Unlike mammalian development, amphibian metamorphosis can be easily manipulated by blocking the synthesis of endogenous T3 or by adding physiological concentrations of T3 to the tadpole rearing water, even though different organs and/or tissues undergo vastly different transformations (12, 56).
Using this model system, we have shown previously that the mRNAs of TR interacting cofactors SRC2, SRC3, and p300 are expressed during metamorphosis, among which SRC3 is upregulated during both natural and T3-induced metamorphosis, supporting a role for this coactivator (47). To directly investigate the role of coactivator recruitment by TR in mediating the developmental effects of T3 in vivo, we introduced a dominant negative form of SRC3 (F-dnSRC3) into developing animals through sperm-mediated transgenesis. We showed that F-dnSRC3 inhibits both natural and T3-induced metamorphosis and the expression of TR target genes by specifically blocking coactivator recruitment but not corepressor release. These results thus identify an essential role of coactivator binding to TR beyond corepressor release in postembryonic development.
| MATERIALS AND METHODS |
|---|
|
|
|---|
For transgenesis, F-dnSRC3 was subcloned into the vector pCGCG (18) under the control of the cytomegalovirus (CMV) promoter, replacing the original green fluorescent protein (GFP) fragment at this location and resulting in the double-promoter construct pCF-dnSRC3CG, which also has the gene for GFP driven by the eye lens-specific
-crystallin promoter.
Animals, transgenesis, and animal treatment. Wild-type tadpoles of the African clawed frog Xenopus laevis were obtained from Xenopus I, Inc. (Dexter, MI), and developmental stages were determined according to Nieuwkoop and Faber (43). Adult female frogs used for oocyte preparation were obtained from NASCO (Fort Atkinson, WI).
Transgenesis was carried out using X. laevis as described previously (18) using the double-promoter construct pCF-dnSRC3CG. Transgenic animals were identified by GFP expression in the eye lens due to the presence of the second promoter, the
-crystallin promoter, driving the expression of GFP.
To study the effect of transgene on T3-induced tail resorption and other external changes, 1-week-old transgenic tadpoles were treated for 7 days with 10 nM T3 diluted in 0.1x MMR (10 mM NaCl-0.2 mM KCl-0.1 mM MgCl2-0.2 mM CaCl2-0.5 mM HEPES, pH 7.5). Both wild-type and transgenic animals were treated in the same container to ensure similar conditions of treatment. To study the effect of the transgene on limb development and changes in the intestine, stage 54 animals were treated with the indicated amount of T3 (two animals per liter of deionized, dechlorinated water). These tadpoles were sacrificed by decapitation after anesthesia (cooling on ice) to isolate tissues for molecular analyses.
Oocyte injection and immunoprecipitation. pSP64-TR, pSP64-RXR (71), and T7Ts-Flag-dnSRC3 were used to synthesize the corresponding mRNAs in vitro with a T7 or SP6 in vitro transcription kit (mMESSAGE mMACHINE; Ambion). The mRNA, at a concentration of 5.75 ng/oocyte, was microinjected into the cytoplasm of 20 X. laevis stage VI oocytes. After incubation overnight at 18°C, the oocytes were lysed by being pipetted in lysis buffer (20 mM HEPES, pH 7.5, 5 mM KCl, 1.5 mM MgCl2, 1 mM EGTA, 10 mM glycerophosphate, 150 mM NaCl, 0.1% NP-40, 1 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride, and protease inhibitor mixture [Roche Applied Science]). After centrifugation at 14,000 rpm for 10 min at 4°C, the supernatant was used for immunoprecipitation with anti-Flag-M2-agarose beads (Sigma). Each lysate was incubated with the beads for 4 h and washed three times in the lysis buffer. The immunoprecipitates were boiled in sodium dodecyl sulfate (SDS) loading buffer, separated on an SDS-polyacrylamide gel, and immunoblotted with indicated antibodies.
Luciferase assays. The cytoplasm of groups of stage VI oocytes was injected with mRNAs encoding TR, RXR, and/or F-dnSRC3 (5.75 ng per oocyte). The reporter plasmid DNA (0.33 ng/oocyte), which contained the T3-dependent TRßA promoter driving the expression of the firefly luciferase (1) was injected into the oocyte nucleus, together with a control construct which contained the herpes simplex virus tk promoter driving the expression of Renilla luciferase (0.03 ng/oocyte). Following incubation overnight at 18°C in the absence or presence of 100 nM T3, oocytes were prepared for luciferase assay by the Dual-Luciferase Reporter Assay system (Promega), according to the manufacturer's recommendations.
Protein extraction and Western blot analysis. Isolated tissues from wild-type and transgenic tadpoles at stage 54 were homogenized on ice in lysis buffer [10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 200 M 4-(2-aminoethyl)-benzenesulfonylfluoride HCl, 5 µg/ml aprotinin, 2 µg/ml leupeptin, and 1 µg/ml pepstatin]. The homogenate was kept on ice for 30 min before centrifugation for 15 min at 4°C (11,000 x g). Equal amounts of the protein extract were then analyzed by Western blotting with anti-Flag antibodies to detect the expression of the transgene.
Chromatin immunoprecipitation (ChIP) assays. The ChIP assay with Xenopus oocytes was performed as described previously (63). For the ChIP assay with tadpole tissues, four tadpoles per treatment group were used. Wild-type and transgenic tadpoles were treated with 10 nM T3 for 2 days in the same container. The ChIP assay was performed as described previously (9, 54) with minor modifications (64). The following antibodies were used in the assay: anti-Xenopus TR (71), anti-acetylated histone H4 (Upstate Biotechnology, Lake Placid, N.Y.), anti-Flag M2-agarose (Sigma), anti-Xenopus SRC3 (generated in rabbits by coinjecting the peptides SGEKRRREQESK and DHLEDGSNLDARQRYE), and anti-Xenopus SMRT antibody (generated by immunizing a rabbit with the polypeptide KSKKQEMIKKLSTTNRSEQE, located in a 2-kb cDNA fragment corresponding to the C-terminal part encompassing the TR-binding domain of the Xenopus laevis SMRT) (64). The primers used in the oocyte ChIP assay were (5' to 3' direction) TGCCTGTGTCTATACTGATGGGAT and CATTTTACCAACAGTACCGGAATGC, producing a 190-bp fragment containing the TRE region of the construct TRE-Luc.
The DNA from the ChIP assay with tadpole tissues was analyzed by quantitative PCR in duplicate on an ABI 7000 (Applied Biosystems) system using promoter-specific primers and 6-carboxyfluorescein-labeled TaqMan probes (Applied Biosystems). To ensure the validity of the PCR for each assay, six twofold serial dilutions from a large batch of ChIP input DNA prepared from intestines prepared especially to serve as standards were used for the quantification of the experimental samples. The calculated standard curves ranged in slope from 3.30 to 3.50, where theoretical amplification has a slope of 3.32. Also included was a no-template control, where double-distilled water was added instead of sample DNA as a control for PCR product contamination. Results from the experimental samples were within the range of the standard curve. The primers used for the quantitative PCR were as follows (5' to 3'): CCCCTATCCTTGTTCGTCCTC and GCGCTGGGCTGTCCT for the TRE region of the TRßA promoter and GGACGCACTAGGGTTAAGTAAGG and TCTCCCAACCCTACAGAGTTCAA for the TRE region of the TH/bZIP promoter. The 6-carboxyfluorescein-labeled probes were (5' to 3') CCTAGGCAGGTCATTTC and ATGAGGCTGAGCATTCA for the TRßA and the TH/bZIP promoters, respectively.
RNA isolation and reverse transcriptase PCR (RT-PCR). RNA was isolated using the Trizol reagent (Invitrogen) per the manufacturer's recommendations. RT-PCRs were carried out with the Superscript One-Step RT-PCR kit (Invitrogen). The expression of the ribosomal protein L8 (Rpl8) was used as an internal control (58). The sequences of the primers used were (5' to 3') CGTGGTGCTCCTCTTGCCAAG and GACGACCAGTACGACGAGCAG for rpl8 (58), CCTGATGCATGCAAAACT and GTTCATCCTGGAAAGCAG for ST3 (46), CACTTAGCAACAGGGATCAGC and CTTGTCCCAGTAGCAATCATC for TH/bZIP (19), ATAGTTAATGCGCCCGAGGGTGGA and CTTTTCTATTCTCTCCACGCTAGC for TRßA (74), CATCATGATTCCTGGTAACCGA and AAATTTCCATTTTCTGCTGTGC for BMP-4 (42), and GGGCAGTGGACATCACCAC and GTTGACCTTGGTCTGGGCC for xhh (60). The sequences of the primers used for the detection of F-dnSRC3 in transgenic animals were (5' to 3') ACCGGTGCCATGGACTAC and CTAGTCACTAGTGAATTCTCACTTGGCCAGTGTCCTTCCAGTC. A total of 0.5 µg of total RNA was used in a 25-µl reaction mixture, under the following reaction conditions: 42°C for 30 min for the RT reaction, followed by 21 to 25 cycles, each consisting of 94°C for 30 s, 55°C for 30 s, and 72°C for 30 s. The resulting products were analyzed on an agarose gel stained with ethidium bromide.
Histological analysis of the intestine. The intestines of the tadpoles were dissected and fixed for 2 h at room temperature in 4% paraformaldehyde-60% phosphate-buffered saline, cryoprotected in 0.5 M sucrose in 60% phosphate-buffered saline and embedded in OCT medium (TissueTek). The intestines were sectioned in a cryotome at 7.5 µm. Sections were visualized with methyl green pyronin Y (Muto, Tokyo, Japan) (29).
| RESULTS |
|---|
|
|
|---|
|
A dominant negative SRC3 inhibits gene activation by TR in the frog oocyte. To generate a dominant negative form of SRC3, we reasoned that a truncated protein comprising only the receptor interaction domain of SRC3 might be able to function as a dominant negative inhibitor of coactivator binding to TR, thus inhibiting gene activation by liganded TR. Therefore, we generated a truncated form of SRC3 (Fig. 2A), F-dnSRC3, consisting of an N-terminal Flag tag, followed by the SV40 NLS and the receptor interaction domain of SRC3 (aa 600 to 751) (35). To verify the expression and localization of F-dnSRC3, its mRNA was synthesized in vitro and microinjected into the oocyte cytoplasm. As a control, the mRNA encoding Flag-tagged Xenopus TR (F-TR), which localizes to the nucleus, was coinjected. After overnight incubation, the nuclear and cytoplasmic fractions of the injected oocytes were isolated and subjected to Western blotting using the anti-Flag antibody. The results showed that both F-TR and F-dnSRC3 were efficiently expressed and localized in the nucleus (Fig. 2B).
|
We next tested the ability of F-dnSRC3 to inhibit transcriptional activation by liganded TR. Again, we microinjected the reporter vector harboring the T3-dependent Xenopus TRßA promoter into the nuclei of oocytes together with the internal control plasmid harboring the Renilla luciferase gene. The cytoplasm of groups of oocytes was injected with mRNAs encoding TR, RXR, and/or F-dnSRC3. The oocytes were incubated overnight in the absence or presence of T3, followed by luciferase assays. As shown in Fig. 3A, F -dnSRC3 had no effect on basal transcription in the absence of TR/RXR (Fig. 3A, lanes 1 and 2). However, the activation by TR/RXR in the presence of T3 was inhibited by F-dnSRC3 (Fig. 3A, compare lanes 5 and 4). To investigate whether this dominant negative effect of F-dnSRC3 was due to its T3-dependent recruitment to the promoter, ChIP assays were carried out using antibodies against TR and F-dnSRC3. The results revealed that F-dnSRC3 was recruited to the promoter in a T3-dependent fashion, whereas TR bound constitutively to the TRßA promoter in the oocyte (Fig. 3B). Moreover, in the presence of F-dnSRC3, the T3-dependent recruitment of endogenous SRC3 to the promoter was impaired (Fig. 3B). These results suggest that F-dnSRC3 functions as an effective dominant negative to block endogenous coactivators in gene regulation by TR and that the recruitment of SRC3 or other TR-binding coactivators by liganded TR is essential for gene activation in vivo.
|
-crystallin promoter (Fig. 4A) (18), which is functional only in the eye lens. This allowed us to rear both wild-type and transgenic animals together to avoid variations in growth and treatment conditions, because transgenic animals could be easily identified at the end of the treatment by their green eyes under a fluorescent microscope due to the GFP expression in the eyes (Fig. 4B). After the transgenesis, the wild-type and sibling transgenic (green-eyed) animals were reared together, and the transgenic animals developed apparently normally (at least after feeding begins at stage 45, when we started monitoring) up to the onset of metamorphosis compared to wild-type siblings. To verify the expression of F-dnSRC3 in the green-eyed transgenic animals, RNA from wild-type and sibling transgenic (green-eyed) tadpoles was isolated and subjected to RT-PCR, which revealed that green eyes correlated with the presence of the transgene mRNA in the tadpoles (Fig. 4C). Furthermore, analysis of the expression of the transgene in different tissues such as the intestine, tail, and brain showed similar expression levels in different organs (Fig. 4D). Western blot analysis confirmed similar levels of F-dnSRC3 protein in different organs of the transgenic but not wild-type animals (Fig. 4E).
|
|
The effect of the F-dnSRC3 transgene on the metamorphosis of internal organs was studied by a histological analysis of the small intestine. The premetamorphic intestine is a simple tubular organ of a monolayer of epithelial cells with little connective tissue and muscles except in the single epithelial fold, the typhlosole, where connective tissue is abundant (57, 77). T3 treatment of premetamorphic tadpoles at stage 54 resulted in the typical metamorphic changes, including the degeneration of the larval epithelium, proliferation of adult epithelial cells, and increase in the thickness of the connective tissue (compare Fig. 6B to A and E to D). On the other hand, the intestine of F-dnSRC3 transgenic tadpoles treated with T3 resembled the intestine of an untreated or premetamorphic animal in structure, although intermediate transformation was evident (Fig. 6C and F). These results, together with observations from external morphological analysis, suggest that F-dnSRC3 inhibits T3-induced metamorphosis of most, if not all, organs and/or tissues.
|
|
The dominant negative SRC3 inhibits metamorphosis by blocking the activation of T3-responsive genes. To investigate the molecular mechanism by which F-dnSRC3 inhibits metamorphosis, we analyzed the expression of known T3 response genes in wild-type and transgenic animals treated with T3. We focused our studies on the intestine because it has been studied extensively at both morphological and molecular levels (56). We analyzed four early or direct T3-response genes, namely, TRßA, TH/bZIP, stromelysin-3 (ST3), and sonic hedgehog (xhh) and a late or indirect T3 response gene, the bone morphogenic protein 4 gene BMP4 (19, 30, 42, 46, 49, 60). All these genes are known to be upregulated in the intestine during T3 treatment or natural metamorphosis. As expected, all genes were induced in the intestine of premetamorphic wild-type tadpoles treated with T3 (Fig. 8, lanes 1 and 2). On the other hand, little induction was observed in transgenic tadpoles treated with T3 (Fig. 8, compare lanes 2 and 3). These results indicate that the F-dnSRC3 interfered with the activation of both early (direct) and late (indirect) T3 response genes, thereby blocking the entire metamorphic gene expression program and thus metamorphosis as well.
|
|
| DISCUSSION |
|---|
|
|
|---|
The ability of TR to repress and activate target genes in a T3-dependent manner and the expression of TR in tadpoles prior to the synthesis of endogenous T3 have led to a dual-function model for TR during frog development (52). The unliganded TR functions to repress T3-inducible genes to prevent precocious metamorphosis. When the animals grow to critical stages, endogenous T3 is synthesized, converting TR to an activator. This leads to the activation of the T3-inducible genes and thus tissue-specific metamorphosis. A role in gene repression by unliganded TR in premetamorphic tadpoles was supported by data showing the recruitment of the corepressors N-CoR, SMRT, and (more recently) TBLR1 to endogenous T3 response gene promoters in tadpoles and their release upon T3 treatment of the tadpoles (2, 53, 64). Additional evidence for gene repression involving HDAC complexes in premetamorphic tadpoles has come from the fact that inhibiting endogenous histone deacetylase activity with the drug trichostatin A leads to histone acetylation and activation of T3-responsive promoters (50, 51, 54). Thus, it is reasonable to believe that T3-induced release of corepressors when T3 becomes available is an important factor in the upregulation of T3-inducible genes required for metamorphosis. This requirement for release of repression by TR has been substantiated recently by the analyses of transgenic tadpoles overexpressing a dominant negative TR that can no longer bind T3. These animals exhibited arrested or delayed metamorphosis (2, 55), accompanied by the inhibition of T3-dependent gene regulation and the retention of corepressors at T3-regulated promoters (2), supporting the hypothesis that corepressor release is important for metamorphosis. However, these studies left unanswered whether activation above derepression is required for metamorphosis.
Here, we used a dominant negative form of Xenopus SRC3 (F-dnSRC3) overexpressed in transgenic animals to investigate the function of coactivators during metamorphosis. We showed that transgenic overexpression of F-dnSRC3 is sufficient to inhibit all aspects of T3-induced and natural metamorphosis that we analyzed. At the molecular level, F-dnSRC3 overexpression in transgenic tadpoles specifically blocked T3-induced activation of T3 response genes, e.g., TRßA, TH/bZIP, ST3, xhh, and BMP4 in tadpoles. In addition, we showed that F-dnSRC3 is recruited in a T3-dependent manner to target promoters and, more importantly, competes away the recruitment of endogenous SRC3 to these promoters, leading to reduced histone acetylation at the promoters. Expectedly, F-dnSRC3 did not interfere with the recruitment of endogenous corepressors such as SMRT by unliganded TR to the T3 target promoter or their release when T3 is present. Despite the corepressor release, T3-induced gene upregulation and tissue transformation were all inhibited in the transgenic animals, indicating that corepressor release plays only a minor role in gene regulation by T3 during frog development, contrary to the findings from transcription studies with tissue culture cells or frog oocytes.
Even though we have analyzed the recruitment of endogenous SRC3 but not other coactivators due to lack of reagents, F-dnSRC3 is likely to block the binding of other coactivators such as SRC1, SRC2, and p300 to TRs, as there is only a single ligand-induced coactivator-binding site on TRs. Thus, it is not surprising that F-dnSRC3 blocks metamorphosis in all tissues or organs examined, by blocking any potential tissue-specific or ubiquitous coactivator. Furthermore, the phenotypes and gene expression profiles of transgenic animals expressing F-dnSRC3 are essentially identical under our assay conditions to those of transgenic animals expressing a dominant negative TR (2, 55). These would suggest that F-dnSRC3 predominantly affects TR function during this developmental period. Such a conclusion may be understandable given the fact that TR is the central transcription factor for metamorphosis, both necessary and sufficient for mediating the effects of T3 during metamorphosis (2, 3). On the other hand, other nuclear hormone or orphan receptors are also likely to interact with F-dnSRC3. Their function will likely be inhibited by the transgenic F-dnSRC3 as well. However, the roles of these other receptors in metamorphosis are either unknown or secondary to TR action during metamorphosis, even in organs where some may participate, e.g., glucocorticoid receptor in the tail (no ligands for nuclear receptors other than T3 can induce morphological changes in premetamorphic tadpoles) (56). Therefore, the unique property of the metamorphosis model allowed us to correlate the developmental phenotypes to specific gene regulation pathways affected by F-dnSRC3, i.e., gene regulation by TR involving coactivators. More importantly, our results demonstrate that corepressor release is not sufficient for T3 to effect postembryonic organ remodeling and that coactivator recruitment is also required for the developmental effects of T3 in vivo.
In summary, while altering coactivator function through knockouts can lead to developmental defects in mice, the underlying molecular mechanisms are unknown, due to the involvement of the cofactors in transcriptional regulation by many diverse transcription factors and the difficulty in accessing and manipulating postembryonic development in mammals. Our use of F-dnSRC3, comprising only the nuclear receptor-interacting domain, restricts its effect to nuclear receptors. More importantly, the total dependence of the transformations of different organs and/or tissues on T3 makes TR the only transcription factor that controls initiation of the different changes in various organs during this metamorphic period. This unique situation allowed us to illustrate the first example where specific developmental defects are caused by alterations of specific gene regulation pathways involving nuclear receptors. Our experiments connected the phenotype of organ transformation inhibition with the blockade of TR-dependent gene expression pathways via a mutant dominant negative coactivator. In addition, while derepression appears to be a major component of gene activation by T3 in tissue culture cells or frog oocytes, it does not seem to be critical in developing animals, as demonstrated here, further underscoring the importance of in vivo experiments in understanding the molecular mechanisms of nuclear receptor function in development.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Buchholz, D. R., V. S.-C. Hsia, L. Fu, and Y.-B. Shi. 2003. A dominant negative thyroid hormone receptor blocks amphibian metamorphosis by retaining corepressors at target genes. Mol. Cell. Biol. 23:6750-6758.
3. Buchholz, D. R., A. Tomita, L. Fu, B. D. Paul, and Y.-B. Shi. 2004. Transgenic analysis reveals that thyroid hormone receptor is sufficient to mediate the thyroid hormone signal in frog metamorphosis. Mol. Cell. Biol. 24:9026-9037.
4. Burrow, G. N., D. A. Fisher, and P. R. Larsen. 1994. Maternal and fetal thyroid function. N. Engl. J. Med. 331:1072-1078.
5. Carswell, S., and J. C. Alwine. 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. Mol. Cell. Biol. 9:4248-4258.
6. Chen, H., R. J. Lin, R. L. Schiltz, D. Chakravarti, A. Nash, L. Nagy, M. L. Privalsky, Y. Nakatani, and R. M. Evans. 1997. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90:569-580.[CrossRef][Medline]
7. Chen, J. D., and R. M. Evans. 1995. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377:454-457.[CrossRef][Medline]
8. Chubet, R. G., and B. L. Brizzard. 1996. Vectors for expression and secretion of FLAG epitope-tagged proteins in mammalian cells. BioTechniques 20:136-141.[Medline]
9. Damjanovski, S., L. M. Sachs, and Y.-B. Shi. 2002. Function of thyroid hormone receptors during amphibian development, p. 153-176. In A. Baniahmad (ed.), Methods in molecular biology: thyroid hormone receptors, vol. 202. Humana Press, Inc., Totowa, N.J.[CrossRef]
10. Davis, P. J., and F. B. Davis. 1996. Nongenomic actions of thyroid hormone. Thyroid 6:497-504.[Medline]
11. Ding, X. F., C. M. Anderson, H. Ma, H. Hong, R. M. Uht, P. J. Kushner, and M. R. Stallcup. 1998. Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. Mol. Endocrinol. 12:302-313.
12. Dodd, M. H. I., and J. M. Dodd. 1976. The biology of metamorphosis, p. 467-599. In B. Lofts (ed.), Physiology of the amphibia. Academic Press, New York, N.Y.
13. Feng, W., R. C. Ribeiro, R. L. Wagner, H. Nguyen, J. W. Apriletti, R. J. Fletterick, J. D. Baxter, P. J. Kushner, and B. L. West. 1998. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 280:1747-1749.
14. Feng, X., Y. Jiang, P. Meltzer, and P. M. Yen. 2001. Transgenic targeting of a dominant negative corepressor to liver blocks basal repression by thyroid hormone receptor and increases cell proliferation. J. Biol. Chem. 276:15066-15072.
15. Flamant, F., and J. Samarut. 2003. Thyroid hormone receptors: lessons from knockout and knock-in mutant mice. Trends Endocrinol. Metab. 14:85-90.[CrossRef][Medline]
16. Forrest, D., E. Hanebuth, R. J. Smeyne, N. Everds, C. L. Stewart, J. M. Wehner, and T. Curran. 1996. Recessive resistance to thyroid hormone in mice lacking thyroid hormone receptor beta: evidence for tissue-specific modulation of receptor function. EMBO J. 15:3006-3015.[Medline]
17. Fraichard, A., O. Chassande, M. Plateroti, J. P. Roux, J. Trouillas, C. Dehay, C. Legrand, K. Gauthier, M. Kedinger, L. Malaval, B. Rousset, and J. Samarut. 1997. The T3R alpha gene encoding a thyroid hormone receptor is essential for post-natal development and thyroid hormone production. EMBO J. 16:4412-4420.[CrossRef][Medline]
18. Fu, L., D. Buchholz, and Y.-B. Shi. 2002. A novel double promoter approach for identification of transgenic animals: a tool for in vivo analysis of gene function and development of gene-based therapies. Mol. Reprod. Dev. 62:470-476.[CrossRef][Medline]
19. Furlow, J. D., and D. D. Brown. 1999. In vitro and in vivo analysis of the regulation of a transcription factor gene by thyroid hormone during Xenopus laevis metamorphosis. Mol. Endocrinol. 13:2076-2089.
20. Gauthier, K., O. Chassande, M. Plateroti, J. P. Roux, C. Legrand, B. Pain, B. Rousset, R. Weiss, J. Trouillas, and J. Samarut. 1999. Different functions for the thyroid hormone receptors TR
and TRß in the control of thyroid hromone production and post-natal development. EMBO J. 18:623-631.[CrossRef][Medline]
21. Gehin, M., M. Mark, C. Dennefeld, A. Dierich, H. Gronemeyer, and P. Chambon. 2002. The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP. Mol. Cell. Biol. 22:5923-5927.
22. Gothe, S., Z. Wang, L. Ng, J. M. Kindblom, A. C. Barros, C. Ohlsson, B. Vennstrom, and D. Forrest. 1999. Mice devoid of all known thyroid hromone receptors are viable but exhibit disorders of the pituitary-thyroid axis, growth, and bone maturation. EMBO J. 13:1329-1341.
23. Guenther, M. G., W. S. Lane, W. Fischle, E. Verdin, M. A. Lazar, and R. Shiekhattar. 2000. A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes Dev. 14:1048-1057.
24. Heery, D. M., E. Kalkhoven, S. Hoare, and M. G. Parker. 1997. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733-736.[CrossRef][Medline]
25. Hetzel, B. S. 1989. The story of iodine deficiency: an international challenge in nutrition. Oxford University Press, Oxford, United Kingdom.
26. Hong, H., K. Kohli, A. Trivedi, D. L. Johnson, and M. R. Stallcup. 1996. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc. Natl. Acad. Sci. USA 93:4948-4952.
27. Horlein, A. J., A. M. Naar, T. Heinzel, J. Torchia, B. Gloss, R. Kurokawa, A. Ryan, Y. Kamei, M. Soderstrom, C. K. Glass, et al. 1995. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377:397-404.[CrossRef][Medline]
28. Ishizuka, T., and M. A. Lazar. 2003. The N-CoR/histone deacetylase 3 complex is required for repression by thyroid hormone receptor. Mol. Cell. Biol. 23:5122-5131.
29. Ishizuya-Oka, A., Q. Li, T. Amano, S. Damjanovski, S. Ueda, and Y.-B. Shi. 2000. Requirement for matrix metalloproteinase stromelysin-3 in cell migration and apoptosis during tissue remodeling in Xenopus laevis. J. Cell Biol. 150:1177-1188.
30. Ishizuya-Oka, A., S. Ueda, T. Amano, K. Shimizu, K. Suzuki, N. Ueno, and K. Yoshizato. 2001. Thyroid-hormone-dependent and fibroblast-specific expression of BMP-4 correlates with adult epithelial development during amphibian intestinal remodeling. Cell Tissue Res. 303:187-195.[CrossRef][Medline]
31. Ito, M., and R. G. Roeder. 2001. The TRAP/SMCC/Mediator complex and thyroid hormone receptor function. Trends Endocrinol. Metab. 12:127-134.[CrossRef][Medline]
32. Ito, M., C. X. Yuan, H. J. Okano, R. B. Darnell, and R. G. Roeder. 2000. Involvement of the TRAP220 component of the TRAP/SMCC coactivator complex in embryonic development and thyroid hormone action. Mol. Cell 5:683-693.[CrossRef][Medline]
33. Jepsen, K., O. Hermanson, T. M. Onami, A. S. Gleiberman, V. Lunyak, R. J. McEvilly, R. Kurokawa, V. Kumar, F. Liu, E. Seto, S. M. Hedrick, G. Mandel, C. K. Glass, D. W. Rose, and M. G. Rosenfeld. 2000. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 102:753-763.[CrossRef][Medline]
34. Jones, P. L., and Y.-B. Shi. 2003. N-CoR-HDAC corepressor complexes: roles in transcriptional regulation by nuclear hormone receptors, p. 237-268. In J. L. Workman (ed.), Current topics in microbiology and immunology: protein complexes that modify chromatin, vol. 274. Springer-Verlag, Berlin, Germany.
35. Kim, H. J., S. K. Lee, S. Y. Na, H. S. Choi, and J. W. Lee. 1998. Molecular cloning of xSRC-3, a novel transcription coactivator from Xenopus, that is related to AIB1, p/CIP, and TIF2. Mol. Endocrinol. 12:1038-1047.
36. Kroll, K. L., and E. Amaya. 1996. Transgenic Xenopus embryos from sperm nuclear transplantations reveal FGF signaling requirements during gastrulation. Development 122:3173-3183.[Abstract]
37. LaFranchi, S. 1999. Thyroid function in the preterm infant. Thyroid 9:71-78.[Medline]
38. Lazar, M. A. 1993. Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr. Rev. 14:184-193.[CrossRef][Medline]
39. Li, H., P. J. Gomes, and J. D. Chen. 1997. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc. Natl. Acad. Sci. USA 94:8479-8484.
40. Li, J., J. Wang, J. Wang, Z. Nawaz, J. M. Liu, J. Qin, and J. Wong. 2000. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J. 19:4342-4350.[CrossRef][Medline]
41. Mangelsdorf, D. J., C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. Umesono, B. Blumberg, P. Kastner, M. Mark, and P. Chambon. 1995. The nuclear receptor superfamily: the second decade. Cell 83:835-839.[CrossRef][Medline]
42. Metz, A., S. Knoechel, P. Buechler, M. Koester, and W. Knoechel. 1998. Structural and functional analysis of the BMP-4 promoter in early embryos of Xenopus laevis. Mech. Dev. 74:29-39.[CrossRef][Medline]
43. Nieuwkoop, P. D., and J. Faber. 1956. Normal table of Xenopus laevis, 1st ed. North Holland Publishing, Amsterdam, The Netherlands.
44. Nolte, R. T., G. B. Wisely, S. Westin, J. E. Cobb, M. H. Lambert, R. Kurokawa, M. G. Rosenfeld, T. M. Willson, C. K. Glass, and M. V. Milburn. 1998. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395:137-143.[CrossRef][Medline]
45. Onate, S. A., S. Y. Tsai, M. J. Tsai, and B. W. O'Malley. 1995. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354-1357.
46. Patterton, D., W. P. Hayes, and Y. B. Shi. 1995. Transcriptional activation of the matrix metalloproteinase gene stromelysin-3 coincides with thyroid hormone-induced cell death during frog metamorphosis. Dev. Biol. 167:252-262.[CrossRef][Medline]
47. Paul, B. D., and Y.-B. Shi. 2003. Distinct expression profiles of transcriptional coactivators for thyroid hormone receptors during Xenopus laevis metamorphosis. Cell Res. 13:459-464.[CrossRef][Medline]
48. Rachez, C., and L. P. Freedman. 2001. Mediator complexes and transcription. Curr. Opin. Cell Biol. 13:274-280.[CrossRef][Medline]
49. Ranjan, M., J. Wong, and Y. B. Shi. 1994. Transcriptional repression of Xenopus TR beta gene is mediated by a thyroid hormone response element located near the start site. J. Biol. Chem. 269:24699-24705.
50. Sachs, L. M., T. Amano, N. Rouse, and Y. B. Shi. 2001. Involvement of histone deacetylase at two distinct steps in gene regulation during intestinal development in Xenopus laevis. Dev. Dyn. 222:280-291.[CrossRef][Medline]
51. Sachs, L. M., T. Amano, and Y. B. Shi. 2001. An essential role of histone deacetylases in postembryonic organ transformations in Xenopus laevis. Int. J. Mol. Med. 8:595-601.[Medline]
52. Sachs, L. M., S. Damjanovski, P. L. Jones, Q. Li, T. Amano, S. Ueda, Y. B. Shi, and A. Ishizuya-Oka. 2000. Dual functions of thyroid hormone receptors during Xenopus development. Comp. Biochem. Physiol. Biochem. Mol. Biol. 126:199-211.[CrossRef][Medline]
53. Sachs, L. M., P. L. Jones, E. Havis, N. Rouse, B. A. Demeneix, and Y.-B. Shi. 2002. N-CoR recruitment by unliganded thyroid hormone receptor in gene repression during Xenopus laevis development. Mol. Cell. Biol. 22:8527-8538.
54. Sachs, L. M., and Y.-B. Shi. 2000. Targeted chromatin binding and histone acetylation in vivo by thyroid hormone receptor during amphibian development. Proc. Natl. Acad. Sci. USA 97:13138-13143.
55. Schreiber, A. M., B. Das, H. Huang, N. Marsh-Armstrong, and D. D. Brown. 2001. Diverse developmental programs of Xenopus laevis metamorphosis are inhibited by a dominant negative thyroid hormone receptor. Proc. Natl. Acad. Sci. USA 98:10739-10744.
56. Shi, Y.-B. 1999. Amphibian metamorphosis: from morphology to molecular biology. John Wiley & Sons, Inc., New York, N.Y.
57. Shi, Y.-B., and A. Ishizuya-Oka. 1996. Biphasic intestinal development in amphibians: embryogensis and remodeling during metamorphosis. Curr. Top. Dev. Biol. 32:205-235.[Medline]
58. Shi, Y.-B., and V. C.-T. Liang. 1994. Cloning and characterization of the ribosomal protein L8 gene from Xenopus laevis. Biochim. Biophys. Acta 1217:227-228.[Medline]
59. Shiau, A. K., D. Barstad, P. M. Loria, L. Cheng, P. J. Kushner, D. A. Agard, and G. L. Greene. 1998. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937.[CrossRef][Medline]
60. Stolow, M. A., and Y. B. Shi. 1995. Xenopus sonic hedgehog as a potential morphogen during embryogenesis and thyroid hormone-dependent metamorphosis. Nucleic Acids Res. 23:2555-2562.
61. Takeshita, A., G. R. Cardona, N. Koibuchi, C. S. Suen, and W. W. Chin. 1997. TRAM-1, a novel 160-kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid receptor coactivator-1. J. Biol. Chem. 272:27629-27634.
62. Tata, J. R. 1993. Gene expression during metamorphosis: an ideal model for post-embryonic development. Bioessays 15:239-248.[CrossRef][Medline]
63. Tomita, A., D. R. Buchholz, K. Obata, and Y.-B. Shi. 2003. Fusion protein of retinoic acid receptor a with promeyelocytic leukaemia protein or promyelocytic leukaemia zinc-finger protein recruits N-CoR-TBLR1 corepressor complex to repress transcription in vivo. J. Biol. Chem. 278:30788-30795.
64. Tomita, A., D. R. Buchholz, and Y.-B. Shi. 2004. Recruitment of N-CoR/SMRT-TBLR1 corepressor complex by unliganded thyroid hormone receptor for gene repression during frog development. Mol. Cell. Biol. 24:3337-3346.